Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
Rhea-AI Summary
Ekso Bionics (Nasdaq: EKSO) has launched eksoUniversity, a new online continuing education platform for physical therapists (PTs) and physical therapy assistants (PTAs). The platform offers on-demand courses approved for CEUs in over 30 states, specifically targeting professionals working with neurological conditions.
CEO Scott Davis emphasized that while the platform is expected to generate incremental revenue, its primary value lies in educating the neurological physical therapy community about various treatment options. The courses help healthcare professionals maintain their licensing requirements while staying current with evolving treatment methods and technologies.
Positive
- Platform already approved for CEUs in over 30 states
- New revenue stream through continuing education offerings
- Strategic expansion into educational services market
- Potential to increase brand awareness and adoption of exoskeleton technology
Negative
- None.
News Market Reaction 8 Alerts
On the day this news was published, EKSO gained 1.88%, reflecting a mild positive market reaction. Argus tracked a peak move of +18.6% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $178K to the company's valuation, bringing the market cap to $10M at that time.
Data tracked by StockTitan Argus on the day of publication.
On-demand courses already approved for CEUs in over 30 states
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists (“PTs”) and physical therapy assistants (“PTAs”) across the country.
Most states require healthcare professionals to complete a predetermined number of continuing education units (“CEUs”) within each license renewal cycle. The goal of this requirement is to maintain competency in fields that are constantly evolving. This allows providers to stay up-to-date on treatments, techniques, and technologies to provide the best care for their patients.
eksoUniversity offers a growing library of online courses targeted towards PTs and PTAs who work with patients who have neurological conditions. These courses are currently approved for CEUs in over 30 states and can be accessed on-demand for learners.
“We are excited to offer this platform for both current users of exoskeletons and other PTs and PTAs,” said Scott Davis, Chief Executive Officer of Ekso Bionics. “While we believe this platform can generate incremental revenue for us, the greater value is represented through the programs’ ability to educate the neurological physical therapy community on a wide-range of relevant topics and ever-evolving patient treatment options.”
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the availability, content and impacts of eksoUniversity. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to realize the benefits of eksoUniversity, the Company’s inability to obtain adequate financing to fund and grow the Company's operations and necessary to develop or enhance the Company’s technology, the Company’s failure to achieve broad market acceptance of its products, the failure of the Company’s sales and marketing efforts or of partners to market the Company’s products effectively, adverse results in future clinical studies of the Company’s medical device products, the failure of the Company to obtain or maintain patent protection for the Company’s technology, the failure of the Company to obtain or maintain regulatory approval to market the Company’s medical devices, lack of product diversification, existing or increased competition, disruptions in the Company’s supply chain, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company’s most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com
FAQ
What is Ekso Bionics' eksoUniversity and when was it launched?
How many states have approved Ekso Bionics' eksoUniversity for continuing education credits?
What type of courses does EKSO's eksoUniversity offer?
How will eksoUniversity benefit Ekso Bionics' business?
Who can access Ekso Bionics' eksoUniversity platform?
